Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals
- Studies have indicated that around 40% of the available drugs on the market offer poor bioavailability
- Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
- The global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value of $2.21 billion by 2026
One of the main concerns associated with marketed drugs is low bioavailability. Bioavailability is the amount of a drug or substance that becomes completely available to the intended biological destination and is a measure of the rate and fraction of the initial dose of the drug that successfully reaches either the site of action or the bodily fluid domain in which the intended target has unimpeded access. Bioavailability is integral to pharmacokinetics, the study of drug movement through the body. Pharmacokinetics is often represented by the acronym ABCD – administration, bioavailability, clearance, and distribution (https://nnw.fm/FwDeX ).
Various studies have indicated that around 40% of available drugs are poorly bioavailable (soluble) (https://nnw.fm/vdHUb ). Many factors can affect the bioavailability of drugs and substances, including:
The size of the drug’s molecule – smaller molecules are more easily absorbed into the body than larger ones
The type of drug administered – some drugs are absorbed more easily through the stomach than others
How much food is eaten – food can slow down the absorption process
The time of day – the absorption of drugs can be affected by factors like the time of day or the mood of the recipient
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a patented technology, DehydraTECH(TM), which improves the bioavailability of active pharmaceutical ingredients (“APIs”), promotes healthier oral ingestion methods and increases the effectiveness of fat-soluble active molecules. DehydraTECH technology is suitable for use with various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Currently, DehydraTECH-CBD is being studied for the potential treatment of hypertension and heart disease, epilepsy, dementia and diabetes.
Lexaria’s DehydraTECH solves common problems experienced in the pharmaceutical industry. DehydraTECH technology can increase bioabsorption by up to 10x, reduce the onset time from up to 1-2 hours to just minutes, mask the unwanted taste, delivers drugs into the bloodstream more effectively, and provides a higher ratio of drug delivery expected to lower overall drug costs.
The global pharmaceutical drug delivery market size is projected to reach $2.21 billion by 2026, growing at a CAGR of 5.9%. The market was valued at $1.66 billion in 2021. This growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements – including new product launches (https://nnw.fm/dQR9p ).
Understanding the bioavailability of a drug is crucial for clinicians looking for the most appropriate route of administration and schedule for delivering the drug. Lexaria is currently studying its DehydraTECH and DehydraTECH-CBD for indications including epilepsy, high blood pressure, dementia, diabetes and more.
The company’s most recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. These findings further support Lexaria’s efforts and clinical trials, which are currently being explored for hypertension, dementia, diabetes and other indications where DehydraTECH technology may offer solutions in indications where there is an underserved medical need.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Studies have indicated that around 40% of the available drugs on the market offer poor bioavailability
- Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
- The global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value of $2.21 billion by 2026
One of the main concerns associated with marketed drugs is low bioavailability. Bioavailability is the amount of a drug or substance that becomes completely available to the intended biological destination and is a measure of the rate and fraction of the initial dose of the drug that successfully reaches either the site of action or the bodily fluid domain in which the intended target has unimpeded access. Bioavailability is integral to pharmacokinetics, the study of drug movement through the body. Pharmacokinetics is often represented by the acronym ABCD – administration, bioavailability, clearance, and distribution (https://nnw.fm/FwDeX ).
Various studies have indicated that around 40% of available drugs are poorly bioavailable (soluble) (https://nnw.fm/vdHUb ). Many factors can affect the bioavailability of drugs and substances, including:
The size of the drug’s molecule – smaller molecules are more easily absorbed into the body than larger ones
The type of drug administered – some drugs are absorbed more easily through the stomach than others
How much food is eaten – food can slow down the absorption process
The time of day – the absorption of drugs can be affected by factors like the time of day or the mood of the recipient
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a patented technology, DehydraTECH(TM), which improves the bioavailability of active pharmaceutical ingredients (“APIs”), promotes healthier oral ingestion methods and increases the effectiveness of fat-soluble active molecules. DehydraTECH technology is suitable for use with various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Currently, DehydraTECH-CBD is being studied for the potential treatment of hypertension and heart disease, epilepsy, dementia and diabetes.
Lexaria’s DehydraTECH solves common problems experienced in the pharmaceutical industry. DehydraTECH technology can increase bioabsorption by up to 10x, reduce the onset time from up to 1-2 hours to just minutes, mask the unwanted taste, delivers drugs into the bloodstream more effectively, and provides a higher ratio of drug delivery expected to lower overall drug costs.
The global pharmaceutical drug delivery market size is projected to reach $2.21 billion by 2026, growing at a CAGR of 5.9%. The market was valued at $1.66 billion in 2021. This growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements – including new product launches (https://nnw.fm/dQR9p ).
Understanding the bioavailability of a drug is crucial for clinicians looking for the most appropriate route of administration and schedule for delivering the drug. Lexaria is currently studying its DehydraTECH and DehydraTECH-CBD for indications including epilepsy, high blood pressure, dementia, diabetes and more.
The company’s most recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. These findings further support Lexaria’s efforts and clinical trials, which are currently being explored for hypertension, dementia, diabetes and other indications where DehydraTECH technology may offer solutions in indications where there is an underserved medical need.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
